Active Studies

Showing 11-20 trials of 201 total

• Cancer

  Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology [H3E-US-S130]

  This trial is not currently enrolling

  The purpose of this study is to compare the regimens of pemetrexed, carboplatin with pemetrexed maintenance and paclitaxel, carboplatin, bevacizumab with bevacizumab maintenance in patients with Stage IIIB or IV nonsquamous non-small cell lung cancer.

• Cancer

  A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with each of the Regimens [NSABP B-40]

  This trial is not currently enrolling

  RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor ...

• Cancer

  NSABP PROTOCOL B-41: A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response

  This trial is not currently enrolling

  The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC followed by paclitaxel plus trastuzumab or lapatinib or both ...

• Hepatology

  A Randomized, Parallel Group, Dose-Ranging Study to Evaluate Efficacy , Safety, Pharmacokinetics, and Antiviral Activity of VX 222 and Teleprevir in Combination With and Without Pegasys® and Copegus® in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C [Protocol:VX09-222-103]

  This trial is not currently enrolling

  The purpose of this study is to assess the safety and efficacy of combination treatment with VX-222 and telaprevir administered for 12 weeks with and without peginterferon-alfa-2a and/or ribavirin. The subjects enrolled in this study are chronically infected with hepatitis C virus (HCV) genotype 1 ...

• Cancer

  A prospective evaluation of Cyberknife Stereotactic Radiosurgery for low and intermediate risk prostate cancer: emulating HDR brachytherapy dosimetry

  This trial is not currently enrolling

  The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.

• Cancer

  A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma [Protocol:TH-CR-404]

  This trial is not currently enrolling

  The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.

• Cancer

  A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole [Protocol: CRAD001Y2301]

  This trial is not currently enrolling

  There are no treatments specifically approved after recurrence or progression on a NSAI. In light of the need for new treatment options for postmenopausal women after failure of prior non steroidal aromatase inhibitors (NSAI) therapy, the purpose of this Phase III study is to compare efficacy and ...

• Multiple Sclerosis

  Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon B-1a) in Patients with Relapsing-Remitting Multiple Sclerosis [Protocol: 205MS301]

  This trial is not currently enrolling

  The existing scientific and clinical experience with DAC HYP supports its further investigation in the management of multiple sclerosis (MS). This study is being conducted to determine the superiority of DAC HYP compared to IFN β-1a in preventing MS relapse in subjects with relapsing remitting MS ...

• A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.

  This trial is not currently enrolling

  The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.

• Gynecology and Obstetrics

  (NSABP B-31) A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC --> T) to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC --> T + H) in Node Positive Breast Cancer Patients who have Tumors that Overexpress HER2

  This trial is not currently enrolling

  RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to ...